Business
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the Un...
About this update from Medipharm Labs Corp.
[{"type":"text","content":"\n\n\n\n MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n MediPharm Labs holds unique US Food and Drug Administration (FDA) site registration in relation to the manufacturing and release of pharmaceutical cannabis products.\n \n\n MediPharm is the only US FDA Audited purpose-built commercial cannabis facility in\n \n Canada\n \n . One of a handful globally.\n \n\n The possible rescheduling of cannabis in the US opens new opportunities for MediPharm in categories where the Company maintains a competitive advantage.\n \n\n\n\n\n TORONTO\n \n\n ,\n \n\n Aug. 13, 2025\n \n\n /CNW/ - MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (\"MediPharm\", \"MediPharm Labs\" or the \"Company\") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to share insights on its US FDA site registration in relation to the possible rescheduling of cannabis in\n \n the United States\n \n .\n \n\n\n\n\n\n\n\n\n Communication from the US Federal Government and various media reports have indicated that the administration is reviewing the rescheduling of cannabis federally in the US. Speculation is that this will mean changing the classification of cannabis from a Schedule I drug to a Schedule III drug.\n \n\n\n What rescheduling means for cannabis in\n \n the United States\n \n :\n \n\n\n\n The rescheduling would recognize the medical benefits of cannabis at a federal level.\n \n\n Schedule III registration would drastically expand the possibility for US based research on medical cannabis products. Current, Schedule I drug classification puts controls in place that make it difficult for this research to be funded and undertaken today.\n \n\n This would open up the possibility for the US to expand special access medical cannabis programs, like those in\n \n Canada\n \n ,\n \n Australia\n \n and\n \n Germany\n \n .\n \n\n\n\n How MediPharm is best positioned in the event of rescheduling cannabis in the US:\n \n\...